Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
F 19.91 3.16% 0.61
FGEN closed up 3.16 percent on Friday, April 16, 2021, on 2.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical FGEN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 3.16%
Narrow Range Bar Range Contraction 3.16%
Wide Bands Range Expansion 3.16%
Oversold Stochastic Weakness 3.16%
1,2,3 Retracement Bearish Bearish Swing Setup 3.37%
180 Bearish Setup Bearish Swing Setup 3.37%
Older End-of-Day Signals for FGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 5 hours ago
Up 2% about 5 hours ago
Up 1% about 6 hours ago
60 Minute Opening Range Breakout about 7 hours ago
Down 2 % about 8 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


FibroGen, Inc Description

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Pancreatic Cancer Chronic Kidney Disease Anemia Blindness Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Collagen Cornea Treatment Of Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical

Is FGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 57.2088
52 Week Low 18.12
Average Volume 1,734,066
200-Day Moving Average 41.53
50-Day Moving Average 37.79
20-Day Moving Average 27.65
10-Day Moving Average 22.55
Average True Range 2.22
ADX 41.88
+DI 13.88
-DI 44.46
Chandelier Exit (Long, 3 ATRs ) 29.46
Chandelier Exit (Short, 3 ATRs ) 24.78
Upper Bollinger Band 41.41
Lower Bollinger Band 13.90
Percent B (%b) 0.22
BandWidth 99.50
MACD Line -5.11
MACD Signal Line -4.51
MACD Histogram -0.6008
Fundamentals Value
Market Cap 1.81 Billion
Num Shares 91 Million
EPS 0.46
Price-to-Earnings (P/E) Ratio 42.91
Price-to-Sales 29.82
Price-to-Book 8.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.55
Resistance 3 (R3) 21.39 20.70 21.27
Resistance 2 (R2) 20.70 20.28 20.77 21.18
Resistance 1 (R1) 20.30 20.02 20.50 20.46 21.09
Pivot Point 19.61 19.61 19.71 19.68 19.61
Support 1 (S1) 19.21 19.19 19.41 19.37 18.73
Support 2 (S2) 18.52 18.93 18.59 18.64
Support 3 (S3) 18.12 18.52 18.55
Support 4 (S4) 18.28